Table 2. Reported outcomes by Chang et al. (1) with SABR vs. lobectomy for medically-operable patients with esNSCLC.
| Outcomes | SABR | Lobectomy | P |
|---|---|---|---|
| Patients | 31 | 27 | |
| Median follow up | 40.2 months | 35.4 months | |
| Deaths | 1 | 6 | |
| 1-year OS | 100% | 88% | |
| 3-year OS | 95% | 79% | 0.037 |
| 3-year RFS | 86% | 80% | 0.54 |
| Total recurrences | 6 | 3 | |
| Local | 1 | 0 | |
| Regional | 4 | 1 | |
| Distant | 1 | 2 | |
| 3-year freedom from | |||
| Local failure | 96% | 100% | 0.44 |
| Regional failure | 90% | 96% | 0.32 |
| Distant failure | 97% | 91% | 0.42 |
| Number of patients with toxicity [%] | |||
| Grade 3 | 3 [10] | 11 [41] | |
| Grade 4 | 0 [0] | 1 [4] | |
| Grade 5 | 0 [0] | 1 [4] | |
SABR, stereotactic ablative radiotherapy; esNSCLC, early stage non-small cell lung cancer; OS, overall survival; RFS, recurrence-free survival.